{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:10:58Z","timestamp":1791274258682,"version":"4.1.0"},"reference-count":60,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,2,15]]},"DOI":"10.2169\/internalmedicine.5926-25","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T22:10:23Z","timestamp":1753308623000},"page":"520-525","source":"Crossref","is-referenced-by-count":6,"title":["Back to the Physiology: Renal Tubular Handling of Uric Acid and Emerging Strategies for Managing Hyperuricemia"],"prefix":"10.2169","volume":"65","author":[{"given":"Tomoaki","family":"Takata","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Isomoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant 34: 1803-1805, 2019.","DOI":"10.1093\/ndt\/gfz174"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 13: 621-630, 2009.","DOI":"10.1007\/s10157-009-0199-x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tang Y, Jiang J, Zhao Y, Du D. Aging and chronic kidney disease: epidemiology, therapy, management and the role of immunity. Clin Kidney J 17: 1-16, 2024.","DOI":"10.1093\/ckj\/sfae235"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kon S, Konta T, Ichikawa K, et al. Association between renal function and cardiovascular and all-cause mortality in the community-based elderly population: results from the Specific Health Check and Guidance Program in Japan. Clin Exp Nephrol 22: 346-352, 2018.","DOI":"10.1007\/s10157-017-1455-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Marreiros C, Viegas C, Simes D. Targeting a silent disease: vascular calcification in chronic kidney disease. Int J Mol Sci 23: 16114, 2022.","DOI":"10.3390\/ijms232416114"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sofue T. Hyperuricemia: the third key player for nephrosclerosis with ischemia. Hypertens Res 46: 1707-1709, 2023.","DOI":"10.1038\/s41440-023-01294-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Zeng X, Yang Y. Molecular mechanisms underlying vascular remodeling in hypertension. Rev Cardiovasc Med 25: 72, 2024.","DOI":"10.31083\/j.rcm2502072"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hill GS, Heudes D, Bari\u00e9ty J. Morphometric study of arterioles and glomeruli in the aging kidney suggests focal loss of autoregulation. Kidney Int 63: 1027-1036, 2003.","DOI":"10.1046\/j.1523-1755.2003.00831.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Guyton AC. Blood pressure control - special role of the kidneys and body fluids. Science 252: 1813-1816, 1991.","DOI":"10.1126\/science.2063193"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yamamoto M, Takata T, Hanada H, et al. Zinc deficiency induces hypertension by paradoxically amplifying salt sensitivity under high salt intake in mice. Clin Exp Nephrol 28: 728-739, 2024.","DOI":"10.1007\/s10157-024-02478-7"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takata T, Isomoto H. The versatile role of uromodulin in renal homeostasis and its relevance in chronic kidney disease. Intern Med 63: 17-23, 2024.","DOI":"10.2169\/internalmedicine.1342-22"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases. Hypertension 69: 1036-1044, 2017.","DOI":"10.1161\/HYPERTENSIONAHA.116.08998"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kochi M, Kohagura K, Oshiro N, et al. Association of blood pressure and hyperuricemia with proteinuria and reduced renal function in the general population. Hypertens Res 46: 1662-1672, 2023.","DOI":"10.1038\/s41440-023-01250-w"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kohagura K, Kochi M, Miyagi T, et al. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res 36: 43-49, 2013.","DOI":"10.1038\/hr.2012.135"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Piani F, Johnson RJ. Does gouty nephropathy exist, and is it more common than we think? Kidney Int 99: 31-33, 2021.","DOI":"10.1016\/j.kint.2020.10.015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19: 640-653, 2002.","DOI":"10.1093\/oxfordjournals.molbev.a004123"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3: 764, 2012.","DOI":"10.1038\/ncomms1756"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wen S, Arakawa H, Tamai I. Uric acid in health and disease: From physiological functions to pathogenic mechanisms. Pharmacol Ther 256: 108615, 2024.","DOI":"10.1016\/j.pharmthera.2024.108615"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol 77: 323-345, 2015.","DOI":"10.1146\/annurev-physiol-021113-170343"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40: 437-442, 2008.","DOI":"10.1038\/ng.106"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kim GH, Jun JB. Altered serum uric acid levels in kidney disorders. Life 12: 1891, 2022.","DOI":"10.3390\/life12111891"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Imbriano LJ, Ilamathi E, Ali NM, Miyawaki N, Maesaka JK. Normal fractional urate excretion identifies hyponatremic patients with reset osmostat. J Nephrol 25: 833-838, 2012.","DOI":"10.5301\/jn.5000074"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Nigam SK, Bhatnagar V. The systems biology of uric acid transporters. Curr Opin Nephrol Hypertens 27: 305-313, 2018.","DOI":"10.1097\/MNH.0000000000000427"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Toyoda Y, Miyata H, Uchida N, et al. Vitamin C transporter SVCT1 serves a physiological role as a urate importer: functional analyses and in vivo investigations. Pflugers Arch 475: 489-504, 2023.","DOI":"10.1007\/s00424-023-02792-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Toyoda Y, Miyata H, Shigesawa R, Matsuo H, Suzuki H, Takada T. SVCT2\/SLC23A2 is a sodium-dependent urate transporter: functional properties and practical application. J Biol Chem 299: 104976, 2023.","DOI":"10.1016\/j.jbc.2023.104976"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 67: 1739-1742, 2005.","DOI":"10.1111\/j.1523-1755.2005.00273.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression. J Am Soc Nephrol 16: 3553-3562, 2005.","DOI":"10.1681\/ASN.2005050572"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Zhang J, Lei W, Zhou J, Zhang Y, Huang F, Chen M. Uric acid promotes aortic valve calcification via mediating valve interstitial cell osteogenic differentiation and endothelial dysfunction. FASEB J 39: 1-21, 2025.","DOI":"10.1096\/fj.202402831R"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Dempsey B, Pereira da Silva B, Cruz LC, et al. Unraveling the effects of uric acid on endothelial cells: a global proteomic study. Redox Biol 82: 103625, 2025.","DOI":"10.1016\/j.redox.2025.103625"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Mazzali M, Kim YG, Suga S, et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 71: 900-905, 2001.","DOI":"10.1097\/00007890-200104150-00014"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Perlstein TS, Gumieniak O, Hopkins PN, et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 66: 1465-1470, 2004.","DOI":"10.1111\/j.1523-1755.2004.00909.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Semenikhina M, Mathew RO, Barakat M, Van Beusecum JP, Ilatovskaya DV, Palygin O. Blood pressure management strategies and podocyte health. Am J Hypertens 38: 85-96, 2025.","DOI":"10.1093\/ajh\/hpae120"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Takata T, Isomoto H. Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: renoprotective mechanisms beyond glycemic control. Int J Mol Sci 22: 4374, 2021.","DOI":"10.3390\/ijms22094374"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kanbay M, Copur S, Bakir CN, Covic A, Ortiz A, Tuttle KR. Glomerular hyperfiltration as a therapeutic target for CKD. Nephrol Dial Transplant 39: 1228-1238, 2024.","DOI":"10.1093\/ndt\/gfae027"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Khan SR, Canales BK, Dominguez-Gutierrez PR. Randall's plaque and calcium oxalate stone formation: role for immunity and inflammation. Nat Rev Nephrol 17: 417-433, 2021.","DOI":"10.1038\/s41581-020-00392-1"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sellmayr M, Hernandez Petzsche MR, Ma Q, et al. Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease. J Am Soc Nephrol 31: 2773-2792, 2020.","DOI":"10.1681\/ASN.2020040523"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Bardin T, Nguyen QD, Tran KM, et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int 99: 218-226, 2021.","DOI":"10.1016\/j.kint.2020.08.024"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Asahina Y, Sakaguchi Y, Oka T, et al. Association between urinary uric acid excretion and kidney outcome in patients with CKD. Sci Rep 14: 5119, 2024.","DOI":"10.1038\/s41598-024-55809-9"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Sofue T, Nakagawa N, Kanda E, et al. Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One 15: e0240402, 2020.","DOI":"10.1371\/journal.pone.0240402"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Kawashima M, Wada K, Ohta H, Terawaki H, Aizawa Y. Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study. BMC Nephrol 12: 31, 2011.","DOI":"10.1186\/1471-2369-12-31"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Rosolowsky ET, Ficociello LH, Maselli NJ, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 3: 706-713, 2008.","DOI":"10.2215\/CJN.04271007"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Ben-Dov IZ, Kark JD. Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study. Nephrol Dial Transplant 26: 2558-2566, 2011.","DOI":"10.1093\/ndt\/gfq740"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Takae K, Nagata M, Hata J, et al. Serum uric acid as a risk factor for chronic kidney disease in a Japanese community - the Hisayama Study -. Circ J 80: 1857-1862, 2016.","DOI":"10.1253\/circj.CJ-16-0030"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Zhu P, Liu Y, Han L, Xu G, Ran JM. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS One 9: e100801, 2014.","DOI":"10.1371\/journal.pone.0100801"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 53: 796-803, 2009.","DOI":"10.1053\/j.ajkd.2008.12.021"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F; MMKD Study Group. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol 43: 347-352, 2008.","DOI":"10.1016\/j.exger.2008.01.006"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Johnson RJ, Nakagawa T, Jalal D, S\u00e1nchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 28: 2221-2228, 2013.","DOI":"10.1093\/ndt\/gft029"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Ghang B, Park J, Lee JS, et al. Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy. Kidney Int 107: 521-529, 2025.","DOI":"10.1016\/j.kint.2024.10.022"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Wang Y, Dalbeth N, Terkeltaub R, et al. Target serum urate achievement and chronic kidney disease progression in patients with gout and kidney disease. JAMA Intern Med 185: 74-82, 2025.","DOI":"10.1001\/jamainternmed.2024.6212"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res 37: 919-925, 2014.","DOI":"10.1038\/hr.2014.107"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol 16: 58, 2015.","DOI":"10.1186\/s12882-015-0047-z"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant 29: 406-413, 2014.","DOI":"10.1093\/ndt\/gft378"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 382: 2504-2513, 2020.","DOI":"10.1056\/NEJMoa1915833"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med 382: 2493-2503, 2020.","DOI":"10.1056\/NEJMoa1916624"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Chou H, Chiu H, Tsai C, et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant 50: 1620-1627, 2017.","DOI":"10.1093\/ndt\/gfx313"},{"key":"56","doi-asserted-by":"publisher","unstructured":"56. Yanai H, Katsuyama H, Hakoshima M, Adachi H. Urate transporter 1 can be a therapeutic target molecule for chronic kidney disease and diabetic kidney disease: a retrospective longitudinal study. Biomedicines 11: 567, 2023.","DOI":"10.3390\/biomedicines11020567"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Yanai K, Hirai K, Kaneko S, et al. The efficacy and safety of dotinurad on uric acid and renal function in patients with hyperuricemia and advanced chronic kidney disease: a single center, retrospective analysis. Drug Des Devel Ther 17: 3233-3248, 2023.","DOI":"10.2147\/DDDT.S416025"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Kurihara O, Yamada T, Kato K, Miyauchi Y. Efficacy of dotinurad in patients with severe renal dysfunction. Clin Exp Nephrol 28: 208-216, 2024.","DOI":"10.1007\/s10157-023-02419-w"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Amano H, Kobayashi S, Terawaki H. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease. BMC Nephrol 25: 97, 2024.","DOI":"10.1186\/s12882-024-03535-9"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Takata T, Taniguchi S, Mae Y, et al. Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia. Sci Rep 15: 8990, 2025.","DOI":"10.1038\/s41598-025-94020-2"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/4\/65_5926-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:43:11Z","timestamp":1771645391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/4\/65_5926-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5926-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]},"article-number":"5926-25"}}